Saturday, October 24, 2020 2:18:36 PM
eagle8,
I understood what you meant so no problem. This endpoint suggests this trial IS being used as an initial test for benefit found in rGBM as the second most important endpoint. You have seen flipper44’s posts about the ongoing trial in rGBM and the apparent involvement of or contact with Merck employees or a former Merck employee (Mr Roger Perlmutter). The news is going to be “Bigger” than almost anyone realizes yet. Biosectinvestor’s comments about RMAT not long ago also tie in. We are going to have fun and this message board is going to blow up with comments from those who have been watching mostly on the sidelines and I am already very happy for them as they were the ones targeted with FUD to get them to sell. Looking back I remember how concerned I was about investor sentiment at the time of the 2017 annual shareholders meeting and how important it was that each of the leadership team be there to reassure investors. That was a very critical time for retail investor support. Best wishes.
I understood what you meant so no problem. This endpoint suggests this trial IS being used as an initial test for benefit found in rGBM as the second most important endpoint. You have seen flipper44’s posts about the ongoing trial in rGBM and the apparent involvement of or contact with Merck employees or a former Merck employee (Mr Roger Perlmutter). The news is going to be “Bigger” than almost anyone realizes yet. Biosectinvestor’s comments about RMAT not long ago also tie in. We are going to have fun and this message board is going to blow up with comments from those who have been watching mostly on the sidelines and I am already very happy for them as they were the ones targeted with FUD to get them to sell. Looking back I remember how concerned I was about investor sentiment at the time of the 2017 annual shareholders meeting and how important it was that each of the leadership team be there to reassure investors. That was a very critical time for retail investor support. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
